Neurologist Dr. Blane Schilling has launched Memoria, a dietary supplement drink stick aimed at addressing cognitive decline through a specialized four-stage framework. Schilling, a Johns Hopkins-trained physician with twenty-two years of clinical practice, developed the formula after observing gaps in current pharmaceutical treatments for memory loss and cognitive aging.
The Memoria formula is based on what Schilling calls the 4-Stage Cognitive Energy Cycle. This framework identifies four essential stages of thought: Fuel, Fire, Connect, and Repeat. According to Schilling, the aging brain fails when these stages are not supported, specifically noting that current pharmaceutical options often target only a single mechanism like amyloid plaques.
To address the full cycle, the Memoria drink stick includes four specific substrates at clinical doses: micronized creatine monohydrate for energy, sunflower-derived phosphatidylserine for signaling, lion's mane fruiting-body extract for connectivity, and methylcobalamin B12 for cellular replication. The product is designed as a single-serve citrus-berry drink stick to avoid the compliance issues associated with multi-pill regimens.
In a 90-day evaluation of 117 adults aged 57 to 76 with early symptoms, results showed significant changes in cognitive metrics. After 30 days, average daily slips decreased from 7.2 to 2.1, and self-rated sharpness rose from 3 out of 10 to 6. By 90 days, self-rated sharpness reached an average of 8.1 out of 10, and 86% of participants chose to continue the regimen. The evaluation was reviewed by Jane E. Carter, PhD, ABPP-CN, a Board Certified Clinical Neuropsychologist.
Memoria is available exclusively through the manufacturer and is not sold via Amazon or major retail pharmacies like CVS or Walgreens. The company offers a 90-day money-back guarantee for users who do not experience improvements in clarity or sharpness. The product is currently priced at $49 for a 30-day supply as part of an initial production run, with a standard retail price of $84.
The launch comes amid a growing market for cognitive health solutions. Schilling noted that while the pharmaceutical industry has spent billions on Alzheimer's drug development, many new treatments require IV infusions and carry risks of brain swelling or bleeding. Memoria seeks to provide a non-prescription alternative focused on the metabolic and cellular support of the aging brain.
